IPX066: a new intermediate- and extended-release carbidopa-levodopa formulation

By Yacoubian Talene A  

Neurodegenerative Disease Management, Vol. 3, Iss. 2, 2013-04 ,pp. : 123-131

Future Medicine

Access to resources Recommend Favorite

Long-term levodopa/carbidopa intestinal gel in advanced Parkinson’s disease

By Cáceres-Redondo María   Carrillo Fátima   Lama María   Huertas-Fernández Ismael   Vargas-González Laura   Carballo Manuel   Mir Pablo  

Journal of Neurology, Vol. 261, Iss. 3, 2014-03 ,pp. : 561-569

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial

By Tolosa Eduardo   Hernández Basilio   Linazasoro Gurutz   López-Lozano Juan   Mir Pablo   Marey José   Kulisevsky Jaime  

Journal of Neural Transmission, Vol. 121, Iss. 4, 2014-04 ,pp. : 357-366

Springer Publishing Company

Access to resources Recommend Favorite

Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process

By Ferrario J.E.   Delfino M.A.   Stefano A.V.   Zbarsky V.   Douhou A.   Murer M.G.   Raisman-Vozari R.   Gershanik O.S.  

Neuroscience Research, Vol. 47, Iss. 4, 2003-12 ,pp. : 431-436

Elsevier

Access to resources Recommend Favorite

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson’s disease

By Müller T.   Erdmann C.   Muhlack S.   Bremen D.   Przuntek H.   Goetze O.   Woitalla D.  

Journal of Neural Transmission, Vol. 113, Iss. 10, 2006-10 ,pp. : 1441-1448

Springer Publishing Company

Access to resources Recommend Favorite